Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Two abstracts accepted for oral presentation at the 13th London International Cough SymposiumNEW HAVEN, Conn., July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage bi
Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
Trevi Therapeutics Initiated at Buy by Rodman & Renshaw
Trevi Therapeutics Initiated at Buy by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.
Rodman & Renshaw Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Trevi Therapeutics(TRVI.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersVenus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:
Form 144 | Trevi Therapeutics(TRVI.US) Officer Proposes to Sell 136.62K in Common Stocks
SEC FILLINGS DISCLOSED/ May 29, $Trevi Therapeutics(TRVI.US)$ Officer SCIASCIA THOMAS intends to sell 53,368 shares of its common stock on May 29, with a total market value of approximately $136.62K.
Trevi Therapeutics(TRVI.US) Officer Sells US$71,575.78 in Common Stock
$Trevi Therapeutics(TRVI.US)$ Officer GOOD JENNIFER L sold 25,037 shares of common stock on May 20, 2024 at an average price of $2.8588 for a total value of $71,575.78.Source: Announcement What is sta
Trevi Therapeutics(TRVI.US) Officer Sells US$13,276.2 in Common Stock
$Trevi Therapeutics(TRVI.US)$ Officer GOOD JENNIFER L sold 4,578 shares of common stock on May 10, 2024 at an average price of $2.9 for a total value of $13,276.2.Source: Announcement What is statemen
Buy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial Position
Analysts Are Bullish on These Healthcare Stocks: MariMed (MRMD), Trevi Therapeutics (TRVI)
Trevi Therapeutics to Participate in Upcoming Conferences
NEW HAVEN, Conn., May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) fo
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Analysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)
Express News | Trevi Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results
Trevi Therapeutics | 10-Q: Quarterly report
Express News | Trevi Therapeutics Q1 Income From Operations USD -11.906 Million Vs. Ibes Estimate USD -9.84 Million
Express News | Trevi Therapeutics Q1 EPS USD -0.11 Vs. Ibes Estimate USD -0.09
Express News | Trevi Therapeutics Q1 Operating Expenses USD 11.906 Million
Express News | Trevi Therapeutics Q1 Net Income USD -10.902 Million